Articles
Clinical Pharmacology & Therapeutics (2009); 85, 2, 198–203 doi:10.1038/clpt.2008.165
Effects of Vitamin D Supplementation in Atorvastatin-Treated Patients: A New Drug Interaction With an Unexpected Consequence
- 1The Jewish Home of San Francisco, Department of Research, San Francisco, California, USA
- 2Division of Clinical Pharmacology, Department of Medicine, University of California, San Francisco, California, USA
Correspondence: JB Schwartz, (Janice.schwartz@ucsf.edu)
Received 22 May 2008; Accepted 9 July 2008; Published online 27 August 2008.
Abstract
The objective of this study was to determine vitamin D supplementation effects on concentrations of atorvastatin and cholesterol in patients. Sixteen patients (8 men, 8 women; 10 Caucasians, 4 African Americans, 1 Hispanic, 1 Asian), aged 63
11 years (mean
SD, weight 92
31 kg) on atorvastatin (45
33 mg/day) were studied with and without supplemental vitamin D (800 IU/day for 6 weeks). Levels of vitamin D (1,25-dihydroxy(OH) and 25 OH-metabolites), atorvastatin (parent, OH-acid metabolites, lactone, and lactone metabolites), and cholesterol (total, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol) were determined at 0.5, 3, and 10 h after dosing. Vitamin D supplementation increased vitamin D-25-OH metabolites (P < 0.0001) without increased 1,25-dihydroxy vitamin D. Atorvastatin and active metabolite concentrations (P < 0.001) as well as LDL-cholesterol and total-cholesterol levels (97
28 mg/dl vs. 83
30 and 169
35 mg/dl vs. 157
37, P < 0.005) were lower during vitamin D supplementation. The conclusion of the study is that vitamin D supplementation lowers atorvastatin and active metabolite concentrations yet has synergistic effects on cholesterol concentrations.
